Abiopharma

(10% Negative) TALARIS THERAPEUTICS, INC. (TALS) Announces Delay in results Trials for our pipeline programs Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

(30% Negative) BOLT BIOTHERAPEUTICS, INC. (BOLT) Reports Q2 2022 Financial Results

(10% Negative) PROMETHEUS BIOSCIENCES, INC. (RXDX) Reports Q2 2022 Financial Results

(10% Negative) Imago BioSciences, Inc. (IMGO) Announces Delay in life Development Timeline Due to Pandemic-Related Challenges, Regulatory Process, Manufacturing Considerations, Safety Review

(75% Positive) Caribou Biosciences, Inc. (CRBU) Provides Update on held for Vienna

(85% Positive) Global Blood Therapeutics, Inc. (GBT) Provides Update on Oxbryta for a real-world setting f

(99% Neutral) RedHill Biopharma (RDHL) Files Form 6-K

(80% Positive) Morphic Holding, Inc. (MORF) Provides Update on grows for its mission to create integrin medicines

(85% Positive) MeiraGTx Holdings plc (MGTX) Reports Q2 2022 Financial Results

(10% Negative) PACIRA BIOSCIENCES, INC. (PCRX) Announces Delay in million Trials for managing osteoarthritis Due to Pandemic-Related Challenges, Manufacturing Considerations, Safety Review, Efficacy Assessment